Locals on the Hibiscus Coast will benefit from expanded access to the mpox vaccine following a significant announcement by the Government.

Health Minister Dr Shane Reti and Associate Health Minister David Seymour revealed today that Medsafe has granted provisional approval for the Jynneos vaccine.

This approval means the vaccine, which has been available under a specific provision since 2023, will now be more accessible to those at risk.

“While New Zealand’s overall risk remains low, it is crucial that we have robust measures in place,” Dr Reti stated.

“The provisional approval of Jynneos signifies that it meets the necessary standards for safety, efficacy, and quality.”

The vaccine’s approval aligns New Zealand with other countries, such as Australia, where similar exemptions have been in place.

The approval was achieved through close collaboration between Medsafe and Health New Zealand, which acted as an intermediary to facilitate the process.

Currently, there are two confirmed cases of mpox linked to the Winter Pride Festival.

While investigations continue, the risk to the broader community remains minimal.

Health officials are maintaining daily updates and have established a national Incident Management Team to oversee the response.

Dr Reti encouraged those with symptoms to seek support from sexual health clinics and to avoid sexual activity if experiencing symptoms.

He praised the coordinated efforts of health agencies in managing the situation and preventing further spread.

The next step involves the National Immunisation Technical Advisory Group reviewing which groups are most at risk and could benefit the most from the vaccine now that provisional approval is in place.